title: [Intervention effect of quercetin on inflammatory secretion of cardiac fibroblasts].
abstract: To establish neonatal rat cardiac fibroblast inflammatory secretion model by using LPS 100 microg x L(-1) combined with ATP 5 mmol x L(-1), in order to study the inhibitory effect of quercetin on the secretion of inflammatory factors TNF-alpha, IL-1beta and IL-6 of cardiac fibroblasts, further investigate the effect of quercetin on the protein expression of p-NF-kappaB p65 (S276) and p-Akt (S473) by western blot, and discuss the inhibitory effect of quercetin on the inflammatory secretion of cardiac fibroblasts. According to the findings, quercetin with the concentrations between 51.74 micromol x L(-1) and 827.81 micromol x L(-1) had no significant effect on the activity of cardiac fibroblasts. Quercetin with the concentrations of 82.78, 41.39, 20.70 micromol x L(-1) could notably inhibit the increase of TNF-alpha and IL-1beta induced by LPS 100 microg x L(-1) for 3 h and then ATP 5 mmol x L(-1) for 36 h (P < 0.01 or P < 0.05). Quercetin with the concentrations of 82.78, 41.39 micromol x L(-1) could notably inhibit the increase of IL-6 induced LPS 100 microg x L(-1) for 3 h and then ATP 5 mmol x L(-1) for 36 h (P < 0.05), without any notable effect of quercetin with the concentration of 20.70 micromol x L(-1). Quercetin with the concentrations of 82.78, 41.39, 20. 70 micromol x L(-1) could notably inhibit the NF-kappaB p65 (S276) activation induced by LPS 100 microg x L(-1) for 3 h and then ATP 5 mmol x L(-1) for 15 min, with the most significant effect in 20.70 micromol x L(-1). Quercetin with the concentrations of 82.78, 41.39, 20.70 micromol x L(-1) could notably inhibit the increase of p-Akt(473) expression induced by LPS 100 microg x L(-1) for 3 h and then ATP 5 mmol x L(-1) for 240 min (P < 0.05). Therefore, this study believes that quercetin could attenuate the secretion of inflammatory factors TNF-alpha, IL-1beta and IL-6 of cardiac fibroblasts by inhibiting the activation of NF-kappaB p65 (S276) and Akt (473).
authors.forename: Xi-Lan
authors.initials: XL
authors.lastname: Tang
authors.forename: Jian-Xun
authors.initials: JX
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Dong
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Li
authors.forename: Yong-Qiu
authors.initials: YQ
authors.lastname: Zheng
authors.forename: Jin-Cai
authors.initials: JC
authors.lastname: Hou
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D004719:Endomyocardial Fibrosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D005260:Female; D005347:Fibroblasts / Q000187:drug effects* / Q000276:immunology; D006321:Heart / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000235:genetics / Q000276:immunology; D008297:Male; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000276:immunology; D011794:Quercetin / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000276:immunology
chemical_list: D004365:Drugs, Chinese Herbal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D011794:Quercetin; D051057:Proto-Oncogene Proteins c-akt